Alphamab Oncology licenses JSKN016 ex-China rights to Pathos AI for up to USD 2.09 billionPUBT·42 minutes ago09966-0.94%
Alphamab Oncology says China CDE clears JSKN033 Phase 3 trial in recurrent or metastatic cervical cancerPUBT·10 hours ago09966-0.94%
The HK Market's Island of Misfit Toys: Who is Pivoting and Who is Sleepwalking?Global Report·Jul 29 at 04:18 AM02197+7.25%02408+0.31%
Liquidity spillovers trigger a structural repricing in Hong Kong's unclassified cornersGlobal Report·Jul 25 at 04:14 AM09600+2.07%013410.00%
CSPC says China regulator grants breakthrough therapy designation for HER2-positive breast cancer comboPUBT·Jul 14 at 06:01 AM01093-1.34%300765-4.47%
CSPC PHARMA KN026 Combined with HB1801 for Breast Cancer Meets Primary EndpointAASTOCKS News·Jun 10 at 08:45 PM01093-1.34%09966-0.94%
ALPHAMAB-BJSKN016 Clinical Study Results Presented at ASCO Annual MeetingAASTOCKS News·Jun 1 at 08:15 PM09966-0.94%
Alphamab Doses First Patient in Phase II Trial of JSKN033 for Advanced Cervical CancerTip Ranks·May 12 at 07:07 PM09966-0.94%
Alphamab’s KN026 Breast Cancer Trial Secures High-Profile ASCO 2026 SlotTip Ranks·Apr 21 at 11:07 PM09966-0.94%520690-1.84%
